- Supply chain disruptions are not explicitly mentioned, but the report highlights the importance of supplier management and risk mitigation strategies.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. 宜昌東陽光長江藥業股份有限公司
Greenhouse gas emissions & sustainability report data
In its 2018 reporting, YiChang HEC ChangJiang Pharmaceutical Co., Ltd. 宜昌東陽光長江藥業股份有限公司 disclosed greenhouse gas emissions of 19.4K tCO2e/year. By scope: Scope 1: 1.64 tCO2e/year; Scope 2: 19.4K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
19.4K tCO2e/year
2018
Water Usage
346.2K tonnes/year
2018
Waste
553.99 tonnes/year (non-hazardous); 78.33 tonnes/year (hazardous)
2018
Energy Use
16.5M kWh/year
2018
📊 Emissions by Scope (2018)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 1.64 tCO2e/year |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 19.4K tCO2e/year |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
✅ Reported Environmental Achievements
- Year-on-year decrease in energy consumption of 1,803,595 kWh
- 100% classified and standardized treatment rate of industrial waste
- 100% lawful and standardized processing rate of hazardous waste
- 100% standardized discharge of sewage, waste gas, dust and noise pollution
🎯 Climate & Sustainability Targets
🔜 Short-term
- To further strengthen our market position in the anti-virus area and increase the awareness of our own advantageous
📅 Medium-term
- To expand our product portfolio in the strategic selected areas and develop and purchase other new product lines
🔭 Long-term
- To improve domestic research development and production standards, strengthen the research and develop ability of new drugs with the aim of becoming a leading pharmaceutical enterprise in China
🌱 ESG Focus Areas
EnvironmentalSocialGovernance